Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases.
Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.
Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention.
Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $131.5M
Founded date: 2015
Investors 5
| Date | Name | Website |
| - | ShangPharm... | spiivc.com |
| - | Omega Fund... | omegafunds... |
| - | Timefolio ... | timefolioc... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.09.2018 | Series B | $80M | - |
| 30.06.2016 | Series A | $51.5M | SR One |
Mentions in press and media 16
| Date | Title | Description |
| 09.07.2024 | Lilly to Acquire Morphic | Eli Lilly and Company (NYSE: LLY) is to acquire Morphic Holding, Inc. (NASDAQ: MORF), a Waltham, MA-based biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Lilly will commence a tender o... |
| 08.07.2024 | Eli Lilly купит разработчика лекарств от заболеваний кишечника Morphic за $3,2 млрд | Ведущий препарат компании Morphic — MORF-057 — представляет собой пероральное лечение, которое проходит оценку в двух исследованиях фазы 2 у пациентов с язвенным колитом и в одном исследовании фазы 2 у пациентов с болезнью Крона. Язвенный к... |
| 05.03.2024 | Morphic to Participate in March Investor Conferences | - |
| 03.05.2023 | Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering | - |
| 18.10.2018 | Morphic partners with investor AbbVie on integrin inhibitor development | Last month, Morphic closed an $80 million Series B financing – in which AbbVie Ventures participated – led by Omega Funds and Novo holdings, along with participation from new investors EcoR1 Capital and Invus. AbbVie had also taken part in ... |
| 26.09.2018 | Term Sheet — Wednesday, September 26 | THE UNRAVELING Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop The departures make sense given that Social Capital is no longer a venture firm but rather a “technology holding company.... |
| 26.09.2018 | Morphic Therapeutic Announces $80M | WALTHAM, MA, Morphic Therapeutic announced today that it has completed a $80 million Series B financing. >> Click here for more funding data on Morphic Therapeutic >> To export Morphic Therapeutic funding data to PDF and Exc... |
| 26.09.2018 | Morphic Therapeutic Raises $80M in Series B Financing | Morphic Therapeutic, a Waltham, Mass.-based biotechnology company developing a new generation of oral integrin therapies, completed an $80m Series B financing. The round was co-led by Omega Funds and Novo Holdings with participation from In... |
| 25.09.2018 | Morphic raises $80M in Series B round to fund oral integrin inhibitor development | “With compelling preclinical data across a number of programs, we are accelerating our advance into the clinic,” Morphic CEO Praveen Tipirneni said in a statement. Most human cells express integrins on the surface, but the proteins’ patholo... |
| 30.06.2016 | Morphic Therapeutic Nets $51.5M | WALTHAM, MA, Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A financing to advance multiple programs into the clinic. >>... |
Show more